These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182 [TBL] [Abstract][Full Text] [Related]
27. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. Carr AS; Pelayo-Negro AL; Evans MR; Laurà M; Blake J; Stancanelli C; Iodice V; Wechalekar AD; Whelan CJ; Gillmore JD; Hawkins PN; Reilly MM J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):620-7. PubMed ID: 26243339 [TBL] [Abstract][Full Text] [Related]
28. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy]. Sekijima Y Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679 [TBL] [Abstract][Full Text] [Related]
29. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Lamb YN; Deeks ED Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895 [TBL] [Abstract][Full Text] [Related]
30. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. Rintell D; Heath D; Braga Mendendez F; Cross E; Cross T; Knobel V; Gagnon B; Turtle C; Cohen A; Kalmykov E; Fox J Orphanet J Rare Dis; 2021 Feb; 16(1):70. PubMed ID: 33557882 [TBL] [Abstract][Full Text] [Related]
31. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455 [TBL] [Abstract][Full Text] [Related]
32. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140 [TBL] [Abstract][Full Text] [Related]
33. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547 [TBL] [Abstract][Full Text] [Related]
34. The neuropathy in hereditary transthyretin amyloidosis: A narrative review. Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565 [TBL] [Abstract][Full Text] [Related]
35. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis. Nie T; Heo YA; Shirley M Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865 [TBL] [Abstract][Full Text] [Related]